Ibec Seminar. Prof. Kara Spiller
Engineering Macrophages with Biomaterials for Regenerative Medicine
Kara L. Spiller, PhD, URBN Professor of Biomedical Innovation, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA, USA
The inflammatory response, orchestrated primarily by macrophages, plays a major role in the body’s response to injury, disease, or implantation of a biomaterial. When macrophages function normally, they are a powerful force that promote tissue repair and regeneration, but when their behavior goes awry, healing is impaired. Our goal is to understand the mechanisms by which the inflammatory response orchestrates successful tissue regeneration and to develop novel biomaterial strategies that apply these principles to situations in which tissue regeneration is impaired. In particular, we study macrophages in inflammation, phagocytosis, cellular recruitment, vascularization, cell proliferation, tissue deposition, or remodeling, and we design biomaterials that leverage these findings for improved biomaterials design, enhanced macrophage cell therapy, and personalized medicine. Current projects in the lab are directed towards treatment of pulmonary fibrosis and chronic wound healing through biomaterial-enabled macrophage cell therapies.
Dr. Kara Spiller is the URBN Endowed Professor of Biomedical Innovation in Drexel University’s School of Biomedical Engineering, Science, and Health Systems. Her research focuses on the role of immune cells in tissue repair and regeneration and the design of immunomodulatory biomaterials. Her research is funded by the NIH, the NSF, private foundations, and industry. Her awards include a Fulbright fellowship, the NSF CAREER award, and the United States Dept. of State ASPIRE prize. She has published more than 85 publications in biomaterials and immune engineering, and has 18 issued or pending patents. She is the founding director of the Immune Modulation & Engineering Symposium series in Philadelphia, which is the only annually recurring meeting dedicated to convergent research in translational immunology and engineering. She serves on the board of numerous journals and is a frequent NIH study section member.
